Siva Sagar Taduru

Siva Sagar Taduru

Auto-generated profile, based on publicly available information

Siva Sagar Taduru

Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, Kansas, US

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AMAhmed N. Mahmoud
Ahmed N. Mahmoud
STSiva Sagar Taduru
Siva Sagar Taduru
AMAmgad Mentias
Amgad Mentias
DMDhruv Mahtta
Dhruv Mahtta
ABAmr F. Barakat
Amr F. Barakat
JSJacqueline Saw
Jacqueline Saw

7 October 2022 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
ARAniket S Rali
Aniket S Rali
STSiva S Taduru
Siva S Taduru
LTLena E Tran
Lena E Tran
SRSagar Ranka
Sagar Ranka
KSKelly H Schlendorf
Kelly H Schlendorf
SZSandip K Zalawadiya
Sandip K Zalawadiya
Background: Worsening aortic insufficiency (AI) is a known sequela of prolonged continuous-flow left ventricular assist device (LVAD) support with a significant impact on patient outcomes. While medical treatment may relieve symptoms, it is unlikely to halt progression. Surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are among non-medical interventions available to address post-LVAD AI. Limited data are available on outcomes with either SAVR or TAVR for the management of post-LVAD AI. Methods: The National Inpatient Sample data collected for hospital admissions between the years 2015 and 2018 for patients with pre-existing continuous-flow LVAD undergoing TAVR or SAVR for AI were queried. The primary outcome of interest was a composite of in-hospital mortality, stroke, transient ischaemic attack, MI, pacemaker implantation, need for open aortic valve surgery, vascular complications and cardiac tamponade. Results: Patients undergoing TAVR were more likely to receive their procedure during an elective admission (57.1 versus 30%, p=0.002), and a significantly higher prevalence of comorbidities, as assessed by the Elixhauser Comorbidity Index, was observed in the SAVR group (29 versus 18; p=0.0001). We observed a significantly higher prevalence of the primary composite outcome in patients undergoing SAVR (30%) compared with TAVR (14.3%; p=0.001). Upon multivariable analysis adjusting for the type of admission and Elixhauser Comorbidity Index, TAVR was associated with significantly lower odds of the composite outcome (odds ratio 0.243; 95% CI [0.06–0.97]; p=0.045). Conclusion: In this nationally representative cohort of LVAD patients with post-implant AI, it was observed that TAVR was associated with a lower risk of adverse short-term outcomes compared with SAVR.

1 March 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
ARAniket S. Rali
Aniket S. Rali
SRSagar Ranka
Sagar Ranka
JMJeremy A. Mazurek
Jeremy A. Mazurek
MBMarshall D. Brinkley
Marshall D. Brinkley
ACAri Cedars
Ari Cedars
JMJonathan N. Menachem
Jonathan N. Menachem

1 August 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ARAniket S. Rali
Aniket S. Rali
SRSagar Ranka
Sagar Ranka
PAPrakash Acharya
Prakash Acharya
TBTyler Buechler
Tyler Buechler
RWRobert Weidling
Robert Weidling
ZSZubair Shah
Zubair Shah

1 April 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SRSagar Ranka
Sagar Ranka
TDTarun Dalia
Tarun Dalia
PAPrakash Acharya
Prakash Acharya
STSiva Sagar Taduru
Siva Sagar Taduru
SPSuveenkrishna Pothuru
Suveenkrishna Pothuru
KGKamal Gupta
Kamal Gupta